BOX WARNING
Exacerbation of Ischemic Heart Disease Following Abrupt Withdrawal —Hypersensitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy; exacerbation of angina and, in some cases, myocardial infarction have occurred after abrupt discontinuation of such therapy. When discontinuing chronically administered nadolol, particularly in patients with ischemic heart disease, the dosage should be gradually reduced over a period of one to two weeks and the patient should be carefully monitored. If angina markedly worsens or acute coronary insufficiency develops, nadolol administration should be reinstituted promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician’s advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue nadolol therapy abruptly even in patients treated only for hypertension.
| | |
CORZIDE SUMMARY
CORZIDE (Nadolol and Bendroflumethiazide Tablets) for oral administration combines two antihypertensive agents: CORGARD® (nadolol), a nonselective beta-adrenergic blocking agent, and NATURETIN® (bendroflumethiazide), a thiazide diuretic-antihypertensive. Formulations: 40 mg and 80 mg nadolol per tablet combined with 5 mg bendroflumethiazide.
CORZIDE (Nadolol and Bendroflumethiazide Tablets) is indicated in the management of hypertension.
This fixed combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, it may be more convenient than the separate components.
|
|
NEWS HIGHLIGHTS
Clinical Trials Related to Corzide (Nadolol / Bendroflumethiazide)
Treatment for Prevention of Variceal Rebleeding Guided by the Hemodynamic Response [Recruiting]
This is a prospective trial of random distribution, open, parallel group, in which patients
with esophagic variceal bleeding will be randomized into two treatment groups, after
controlling acute bleeding. All patients received standard medical therapy with b-blockers
and endoscopic ligation (LEV) of esophageal varices.
The control group will be assigned to receive LEV + Nadolol + MNI. The experimental group
will be assigned to receive treatment according to the hemodynamic response.
All patients included in the experimental group received LEV and pharmacological treatment
nadolol alone or combined with MNI or Prazosin (PZ)
Fasting Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and CorzideŽ Tablets 80 mg/5 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's
nadolol/bendroflumethiazide 80 mg/5 mg tablets to King's CorzideŽ 80 mg/5 mg tablets
following a single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fasting
conditions.
Fed Study of Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg and CorzideŽ Tablets 80 mg/5 mg [Completed]
The objective of this study was to investigate the bioequivalence of Mylan's
nadolol/bendroflumethiazide 80 mg/5 mg tablets to King's CorzideŽ 80 mg/5 mg tablets
following a single, oral 80 mg/5 mg (1 x 80 mg/5 mg) dose administered under fed conditions.
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding [Recruiting]
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal
injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic
treatment. Beta-blocker (BB) is effective to lower portal pressure. We hypothesized
combination of GVO and BB can further decrease the rebleeding rate.
Secondary Prophylaxis After Variceal Bleeding in Non-Responders [Completed]
Controlled and randomized study comparing combined treatment (nadolol and endoscopic
ligation) versus nadolol associated with isosorbide mononitrate or prazosin according to
hemodynamic response, in the prevention of esofagic verices rebleeding.
|
|
|
|
Page last updated: 2008-06-10
|
